Market research

SABSW SABSW

NASDAQ USD Not available

Latest close

— —

Loading market data…

Test a moving-average rule with historical data.

Market facts

P/E ratio: 0.05
Analyst target: Not available
Dividend yield: Not available
Beta: 0.54
MarketCapitalization: Not available

Loading price history…

Profile

Company facts

Exchange: NASDAQ
Currency: USD
Sector: Not available
Industry: Not available
ISIN: US78397T1117
P/E ratio: 0.05
Analyst target: Not available
Dividend yield: Not available
Beta: 0.54
MarketCapitalization: Not available

About

About SABSW

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.

Visit company website

Fundamentals are not available

This instrument does not currently have reported company financials in PyInvesting.

No comments yet

Start a focused discussion about SABSW.

SABSW SABSW

Price & volume

Company facts

About SABSW

Fundamentals are not available

Investor discussion

No comments yet